PMID- 29318461
OWN - NLM
STAT- MEDLINE
DCOM- 20180904
LR  - 20181113
IS  - 1435-4373 (Electronic)
IS  - 0934-9723 (Linking)
VI  - 37
IP  - 3
DP  - 2018 Mar
TI  - Ceftriaxone promotes the emergence of AmpC-overproducing Enterobacteriaceae in
      gut microbiota from hospitalized patients.
PG  - 417-421
LID - 10.1007/s10096-018-3186-x [doi]
AB  - Epidemiological data suggest that ceftriaxone may promote the emergence of
      commensal AmpC-overproducing Enterobacteriaceae because of a high biliary
      excretion. We tested this hypothesis in hospitalized patients either treated by
      ceftriaxone alone or receiving no antibiotics. Hospitalized patients with no
      previous antibiotics or hospitalization in the last 3 months, treated only with
      ceftriaxone, were prospectively included. For each ceftriaxone-treated patient, a
      control patient receiving no antibiotics was included. Clinical data and stools
      were collected at T0 (before antibiotics) and T1 (at the end of ceftriaxone
      treatment or at discharge) and T2 (3-6 months after T1) for the
      ceftriaxone-treated patients and at T0 and T1 for control patients.
      Third-generation cephalosporin-resistant Enterobacteriaceae were detected,
      identified by matrix-assisted laser desorption/ionization time-of-flight
      (MALDI-TOF), and characterized genetically. Clonal relatedness was evaluated by
      random amplified polymorphic DNA-polymerase chain reaction (RAPD-PCR). Fifteen
      ceftriaxone and 22 control patients were included. Patients' characteristics did 
      not differ. At T0, 2/15 ceftriaxone-treated versus 1/22 control patients carried 
      third-generation cephalosporin-resistant Enterobacteriaceae (p = 0.6). At T1,
      4/15 (27%) ceftriaxone-treated patients carried AmpC producers versus 0/22
      control patients (p = 0.02). Additionally, two and three subjects carried
      extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae in the
      ceftriaxone and control groups, respectively (p = 1). At T2, three
      ceftriaxone-treated patients still carried AmpC-producing Enterobacteriaceae with
      the same RAPD profile as at T1. In hospitalized subjects with no other selective 
      pressure, treatment by ceftriaxone alone promotes the gut colonization by
      AmpC-overproducing Enterobacteriaceae in over a quarter of patients, with a
      persistent carriage after the end of antibiotic exposure. The ecological impact
      of ceftriaxone should not be underestimated.
FAU - de Lastours, Victoire
AU  - de Lastours V
AUID- ORCID: http://orcid.org/0000-0003-1160-2069
AD  - IAME, UMR-1137, INSERM and Universite Paris Diderot, Sorbonne Paris Cite , Paris,
      France. victoire.de-lastours@aphp.fr.
AD  - Service de Medecine Interne, Hopital Beaujon, APHP, 100 Boulevard General
      Leclerc, 92100, Clichy, France. victoire.de-lastours@aphp.fr.
FAU - Goulenok, Tiphaine
AU  - Goulenok T
AD  - Service de Medecine Interne, Hopital Beaujon, APHP, 100 Boulevard General
      Leclerc, 92100, Clichy, France.
FAU - Guerin, Francois
AU  - Guerin F
AD  - Service de Microbiologie, CHU de Caen, Caen, France.
AD  - Universite de Caen Normandie, EA4655, Caen, France.
FAU - Jacquier, Herve
AU  - Jacquier H
AD  - IAME, UMR-1137, INSERM and Universite Paris Diderot, Sorbonne Paris Cite , Paris,
      France.
AD  - Service de Microbiologie, Hopital Lariboisiere, APHP, Paris, France.
FAU - Eyma, Cindy
AU  - Eyma C
AD  - IAME, UMR-1137, INSERM and Universite Paris Diderot, Sorbonne Paris Cite , Paris,
      France.
FAU - Chau, Francoise
AU  - Chau F
AD  - IAME, UMR-1137, INSERM and Universite Paris Diderot, Sorbonne Paris Cite , Paris,
      France.
FAU - Cattoir, Vincent
AU  - Cattoir V
AD  - Service de Microbiologie, CHU de Caen, Caen, France.
AD  - Universite de Caen Normandie, EA4655, Caen, France.
AD  - Service de Bacteriologie-Hygiene Hospitaliere, CHU de Rennes, Rennes, France.
FAU - Fantin, Bruno
AU  - Fantin B
AD  - IAME, UMR-1137, INSERM and Universite Paris Diderot, Sorbonne Paris Cite , Paris,
      France.
AD  - Service de Medecine Interne, Hopital Beaujon, APHP, 100 Boulevard General
      Leclerc, 92100, Clichy, France.
LA  - eng
GR  - 282004/EU FP7-Health Program Evolution and Transfer of Antibiotic Resistance
PT  - Journal Article
DEP - 20180110
PL  - Germany
TA  - Eur J Clin Microbiol Infect Dis
JT  - European journal of clinical microbiology & infectious diseases : official
      publication of the European Society of Clinical Microbiology
JID - 8804297
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Bacterial Proteins)
RN  - 75J73V1629 (Ceftriaxone)
RN  - EC 3.5.2.6 (AmpC beta-lactamases)
RN  - EC 3.5.2.6 (beta-Lactamases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Bacterial Agents/adverse effects/*pharmacology/therapeutic use
MH  - Bacterial Proteins/metabolism
MH  - Ceftriaxone/adverse effects/*pharmacology/therapeutic use
MH  - *Enterobacteriaceae/drug effects/enzymology/metabolism
MH  - *Enterobacteriaceae Infections/drug therapy/epidemiology/microbiology
MH  - Feces/microbiology
MH  - Female
MH  - Gastrointestinal Microbiome/*drug effects
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Microbial Sensitivity Tests
MH  - Middle Aged
MH  - Prospective Studies
MH  - beta-Lactam Resistance/*drug effects
MH  - beta-Lactamases/metabolism
EDAT- 2018/01/11 06:00
MHDA- 2018/09/05 06:00
CRDT- 2018/01/11 06:00
PHST- 2017/12/04 00:00 [received]
PHST- 2018/01/03 00:00 [accepted]
PHST- 2018/01/11 06:00 [pubmed]
PHST- 2018/09/05 06:00 [medline]
PHST- 2018/01/11 06:00 [entrez]
AID - 10.1007/s10096-018-3186-x [doi]
AID - 10.1007/s10096-018-3186-x [pii]
PST - ppublish
SO  - Eur J Clin Microbiol Infect Dis. 2018 Mar;37(3):417-421. doi:
      10.1007/s10096-018-3186-x. Epub 2018 Jan 10.